
For a broader view of opportunities in surgical automation and related technologies, explore other stocks active in this space via 91 robotics and automation stocks.
Intuitive Surgical develops robotic platforms that aim to make minimally invasive procedures more accessible for hospitals and patients. The firm now carries a market value of about $149.2 billion, reflecting its role as a major medical equipment supplier in this segment.
For Intuitive Surgical, stronger take up of da Vinci in gynecology and other procedures directly reinforces the Narrative catalyst that hinges on broadening global procedure growth and higher system utilization. More hospitals committing capital, training surgeons and dedicating operating rooms supports the view that recurring instruments, accessories and services can remain central to the story as usage deepens across specialties. At the same time, a busier competitive field in soft tissue robotics leans into an existing risk in the Narrative that pricing pressure and new entrants could challenge Intuitive Surgical’s clinical and economic position if hospitals start weighing lower cost alternatives more heavily.
See how these catalysts shape Intuitive Surgical's path to a $487 fair value.
To see whether this thesis is gaining or losing traction, focus on the next couple of earnings updates through 2027, especially the reported global procedure growth rates in gynecology and the share of da Vinci volume coming from outside the U.S., alongside any commentary on pricing or system win rates against rival platforms.
Add Intuitive Surgical to your Watchlist and get alerts as these catalysts play out.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com